Baricitinib associated with significant improvement in RA

Baricitinib associated with significant improvement in RA

(HealthDay)—For patients with rheumatoid arthritis who have had an inadequate response to methotrexate, baricitinib is associated with significant clinical improvements, compared to either placebo or adalimumab, according to a study published in the Feb. 16 issue of the New England Journal of Medicine.

Peter C. Taylor, M.D., Ph.D., from University of Oxford in the United Kingdom, and colleagues conducted a 52-week, phase 3, double-blind controlled trial, in which 1,307 patients with active rheumatoid arthritis who were receiving background therapy with methotrexate were randomly assigned to one of three regimens in a 3:3:2 ratio: (switched to baricitinib after 24 weeks), 4 mg of baricitinib once daily, or 40 mg of (an anti-tumor necrosis factor α monoclonal antibody) every other week.

Using the American College of Rheumatology criteria, the researchers found that more patients had a 20 percent improvement at week 12 with baricitinib versus placebo (70 versus 40 percent; P < 0.001) or adalimumab (70 versus 61 percent; P = 0.014). All major secondary objectives, including inhibition of radiographic progression of joint damage at week 24, were met with baricitinib versus placebo (mean change from baseline, 0.41 versus 0.90; P < 0.001). Compared with placebo, adverse events (including infections) were more frequent through week 24 with baricitinib and adalimumab. Cancers were reported in five patients (two taking baricitinib and three taking placebo). Reductions in neutrophil counts and increases in levels of creatinine and were noted with baricitinib.

"In patients with who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab," the authors write.

The study was supported by Eli Lilly, the manufacturer of baricitinib, and Incyte.

Explore further

76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: Baricitinib associated with significant improvement in RA (2017, February 20) retrieved 18 January 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments